Table 6.
Comparison of targets for key milestones in the full (type 3) review process -(calendar days).
| Target | Mozambique | Namibia | South Africa | Tanzania | Zambia | Zimbabwe |
|---|---|---|---|---|---|---|
| Receipt and validation (A – B) | 15 | 42 | 18 | 20 | 20 | 90 |
| Queuing (B – C) | 180–365 | >365 | No target | 60 | 180 | 90 |
| Primary scientific Assessment (C – D) | No target | No target | No target | 14 | No target | 60 |
| Questions to applicant (Clock stop) (D – E) | 60 | 90 | 42 | 180 | 120 | 60 |
| Review by Expert Committee (G – H) | N/A | No target | No target | 1 | 1–3 | 1 |
| Approval procedure (Admin) | >180 | <30 | 14 | <30 | <30 | 60 |
| Overall approval time (A – I) | 365 (excl. applicant time) | No target | 350 for generics (excl. applicant time) | 252 (excl. applicant time) | 351 (incl. applicant time) | 480 (incl. applicant time) |
N/A, No expert Committee.